CAPRI 2 GOIM Study: Investigate the Efficacy and Safety of a Bio-marker Driven Cetuximab-based Treatment Regimen

• Status: Recruiting
• Trial end date: 2026-06-15
• Target enrollment: 0
• Participant gender: All

Summary

This clinical program aims to evaluate the activity and efficacy of cetuximab continuation of treatment for three lines of therapy with rotation of chemotherapy (FOLFIRI, FOLFOX, irinotecan) in mCRC patients, whose tumors remain RAS/BRAF WT. The study will also evaluate the activity and efficacy of cetuximab re-introduction in combination with irinotecan as third line therapy in the concept of re-challenge for those patients that will be treated in second line with chemotherapy plus anti-angiogenic drugs (FOLFOX plus bevacizumab), having a RAS or BRAF mutant disease at the time of progression after FOLFIRI plus cetuximab first line treatment. A novel characteristic of this program is that the therapeutic algorithm will be defined at each treatment decision (first line, second line and third line) in a prospective fashion in each patient by liquid biopsy assessment of RAS/BRAF status.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Campania "Luigi Vanvitelli"
• Treatments: Cetuximab; Irinotecan

Criteria

Inclusion Criteria:

1. Histologically proven diagnosis of colorectal adenocarcinoma

2. Diagnosis of metastatic disease

3. RAS and BRAF wild-type status of FFPE analysis of primary colorectal cancer and/or related metastasis

4. Measurable disease according to Response Evaluation Criteria in Solid Tumors RECIST criteria, vers.1.1)

5. Male or female patients ≥ 18 years of age

6. ECOG Performance Status 0,1

7. Adequate bone marrow, liver and renal function assessed within 14 days before starting study treatment as defined by the following parameters:

Bone marrow:

• Absolute Neutrophil Count (ANC) ≥ 1.5 x 109/L

• Hemoglobin (Hgb) ≥ 9 g/dL

• Platelets ≥ 100 x 109/L

Liver function:

• Serum total bilirubin ≤ 1.5 x upper limit of normal (ULN) Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and ALT (SGPT) ≤ 2.5 x ULN, except in patients with tumor involvement of the liver who must have AST and ALT ≤ 5 x ULN

Renal function:

• Serum creatinine ≤ 1.5 x ULN or 24-hour clearance ≥ 50 mL/min

8. If female and of childbearing potential, have a negative result on a pregnancy test performed a maximum of 7 days before initiation of study treatment

9. If female and of childbearing potential, or if male, agreement to use adequate contraception (e.g., abstinence, intrauterine device, oral contraceptive, or double-barrier method), during the study and until at least 3 months after last dose of study treatment administration, based on the judgment of the Investigator or a designated associate

10. Signed informed consent obtained before screening.

Exclusion Criteria:

1. Any contraindication to the use of cetuximab, Irinotecan, 5-FU, oxaliplatin, folinic acid,bevacizumab, trifluridine-tipiracil, regorafenib

2. Active uncontrolled infections, active disseminated intravascular coagulation or history of interstitial lung disease

3. Past or current history of malignancies other than colorectal carcinoma, except for curatively treated basal and squamous cell carcinoma of the skin cancer or in situ carcinoma of the cervix

4. Pregnancy (exclusion to be ascertained by a beta hCG test)

5. Breastfeeding

6. Fertile women (<2 years after last menstruation) and men of childbearing potential not willing to use effective means of contraception•

7. Myocardial infarction, unstable angina pectoris, balloon angioplasty (PTCA) with or without stenting within the past 12 months before inclusion in the study, Grade III or IV heart failure (NYHA classification)

8. Cardiac arrhythmias requiring anti-arrhythmic therapy, with the exception of beta blockers or digoxin

9. Medical or psychological impairments associated with restricted ability to give consent or not allowing conduct of the study

10. Previous chemotherapy for the colorectal cancer with the exception of adjuvant treatment, completed at least 6 months before entering the study

11. Participation in a clinical study or experimental drug treatment within 30 days prior to study inclusion or during participation in the study

12. Known or clinically suspected brain metastases

13. History of acute or subacute intestinal occlusion or chronic inflammatory bowel disease or chronic diarrhoea

14. Severe, non-healing wounds, ulcers or bone fractures

15. Uncontrolled hypertension

16. Marked proteinuria (nephrotic syndrome)

17. Known DPD deficiency (specific screening not required)

18. Known history of alcohol or drug abuse

19. A significant concomitant disease which, in the investigating physician's opinion, rules out the patient's participation in the study

20. Absent or restricted legal capacity